OVID · Ovid Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $132.0K | $6.27M | $130.0K | - | $173.0K | $169.0K | $148.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $11.18M | - | $5.87M | $6.46M | $6.66M | - | $7.86M | $12.58M | $10.40M | - |
| SG&A | $6.67M | - | $6.79M | $4.88M | $6.02M | - | $5.54M | $8.10M | $7.17M | - |
| Total Operating Expenses | $17.85M | - | $12.65M | $11.35M | $12.68M | - | $13.40M | $20.69M | $17.57M | - |
| D&A | $35.0K | - | $17.0K | $61.0K | $141.0K | - | $105.0K | $103.0K | $136.0K | - |
| Operating Income | ($17.85M) | - | ($12.52M) | ($5.07M) | ($12.55M) | - | ($13.23M) | ($20.52M) | ($17.42M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($16.99M) | - | ($12.16M) | ($4.68M) | ($10.23M) | - | ($14.01M) | $8.52M | ($11.69M) | - |
| EPS - Basic | - | - | - | - | - | - | ($0.20) | $0.12 | ($0.17) | - |
| EPS - Diluted | - | - | - | - | - | - | ($0.20) | $0.12 | ($0.17) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $94.06M | $13.15M | $20.61M | $28.41M | $21.14M | $26.30M | $15.02M | $29.69M | $30.77M | $27.04M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.88M | $1.96M | $1.71M | $3.95M | $1.95M | $3.19M | $2.71M | $4.72M | $3.60M | $3.70M |
| Current Assets | $160.15M | $74.37M | $28.82M | $42.09M | $45.92M | $55.94M | $65.83M | $80.89M | $93.17M | $109.60M |
| Total Assets | $225.63M | $150.93M | $63.85M | $77.43M | $81.65M | $92.17M | $102.65M | $118.09M | $131.61M | $144.03M |
| Current Liabilities | $15.75M | $8.29M | $6.80M | $8.92M | $9.31M | $10.52M | $11.63M | $14.12M | $8.90M | $11.47M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $27.36M | $20.27M | $19.15M | $21.64M | $22.38M | $23.94M | $26.36M | $29.19M | $53.33M | $56.23M |
| Stockholders' Equity | $198.27M | $130.66M | $44.70M | $55.79M | $59.28M | $68.23M | $76.29M | $88.90M | $78.28M | $87.80M |
| Retained Earnings | ($338.70M) | ($321.71M) | ($331.38M) | ($319.22M) | ($314.53M) | ($304.30M) | ($295.05M) | ($281.04M) | ($289.56M) | ($277.87M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.90M) | - | - | - | ($10.28M) | - | - | - | ($16.69M) | - |
| Investing Cash Flow | $5.95M | - | - | - | $5.10M | - | - | - | $20.19M | - |
| Financing Cash Flow | $88.98M | - | - | - | $13.0K | - | - | - | $228.0K | - |
| CapEx | - | - | - | - | $0 | - | - | - | $19.0K | - |
| Free Cash Flow | - | - | - | - | ($10.28M) | - | - | - | ($16.70M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -9487.1% | -80.9% | -9653.8% | - | -7645.1% | -12140.2% | -11768.2% | - |
| EBITDA margin | - | - | -9474.2% | -79.9% | -9545.4% | - | -7584.4% | -12079.3% | -11676.4% | - |
| Net margin | - | - | -9210.6% | -74.7% | -7873.1% | - | -8096.0% | 5042.0% | -7901.4% | - |
| Free cash flow margin | - | - | - | - | -7907.7% | - | - | - | -11287.2% | - |
| FCF / Net income | - | - | - | - | 1.00 | - | - | - | 1.43 | - |
| R&D / Revenue | - | - | 4447.0% | 103.1% | 5122.3% | - | 4540.5% | 7445.0% | 7025.0% | - |
| SG&A / Revenue | - | - | 5140.2% | 77.8% | 4631.5% | - | 3204.6% | 4795.3% | 4843.2% | - |
| Effective tax rate | - | - | - | - | - | - | - | 0.0% | - | - |
| Return on assets | -7.5% | - | -19.0% | -6.0% | -12.5% | - | -13.6% | 7.2% | -8.9% | - |
| Return on equity | -8.6% | - | -27.2% | -8.4% | -17.3% | - | -18.4% | 9.6% | -14.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.17 | 8.97 | 4.24 | 4.72 | 4.93 | 5.32 | 5.66 | 5.73 | 10.47 | 9.55 |
| Quick ratio | 10.17 | 8.97 | 4.24 | 4.72 | 4.93 | 5.32 | 5.66 | 5.73 | 10.47 | 9.55 |
| Cash ratio | 5.97 | 1.59 | 3.03 | 3.18 | 2.27 | 2.50 | 1.29 | 2.10 | 3.46 | 2.36 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.14 | 1.16 | 1.43 | 1.39 | 1.38 | 1.35 | 1.35 | 1.33 | 1.68 | 1.64 |
| Liabilities / Assets | 0.12 | 0.13 | 0.30 | 0.28 | 0.27 | 0.26 | 0.26 | 0.25 | 0.41 | 0.39 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.08 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | 6.4x | - | - |
| P / B | - | - | - | - | - | - | 1.1x | 0.6x | 2.8x | - |
| P / S | - | - | - | - | - | - | 484.1x | 324.0x | 1457.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | - | -23.7% | 3611.2% | -12.2% | - | 1458.3% | 125.3% | -89.8% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -42.2% | - | 5.3% | 75.3% | 27.9% | - | -10.0% | -44.8% | -17.0% | - |
| Net income growth (YoY) | -66.0% | - | 13.2% | - | 12.5% | - | -24.5% | - | 12.4% | - |
| EPS growth (YoY) | - | - | - | - | - | - | -25.0% | - | 10.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 38.5% | - | - | - | -37.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 234.5% | 91.5% | -41.4% | -37.2% | -24.3% | -22.3% | -24.7% | -19.7% | -35.3% | -33.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$7.25M totalReportable Segment$7.25M · 100.0%
Product / service
$230.70M totalRoyalty License And Termination Agreement$230.70M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Ovid Therapeutics Inc. against the 5 most active filers in the same SIC group.